← All trials
NCT00783172
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2009
- Primary completion
- Aug 1, 2010
- Completion date
- Oct 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 4
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Pennsylvania State UniversityLead sponsor
- National Cancer Institute (NCI)Collaborator
- National Institutes of Health (NIH)Collaborator
- Pennsylvania State UniversityOverall official - principal investigator
- Pennsylvania State UniversitySponsor investigator
- Pennsylvania State UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.